XML 60 R49.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details) $ in Thousands | Mar. 31, 2024 USD ($)
--- | ---
Performance obligations: |
Research and development | $ 45,786
Option rights | 45,000
Total performance obligations | $ 90,786

X
- Definition Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue. + References No definition available. + Details
Name: | carm_RevenueRemainingPerformanceObligationOptionRightsAmount
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue. + References No definition available. + Details
Name: | carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_RevenuePerformanceObligationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant